PURPOSE: Post-myocardial infarction heart failure is a major health concern with limited therapy. Molecular revascularisation utilising granulocyte-macrophage colony stimulating factor (GMCSF) mediated endothelial progenitor cell (EPC) upregulation and stromal cell derived factor-1α (SDF) mediated myocardial EPC chemokinesis, may prevent myocardial loss and adverse remodelling. Vasculogenesis, viability, and haemodynamic improvements following therapy were investigated. PROCEDURES: Lewis rats (n=91) underwent LAD ligation and received either intramyocardial SDF and subcutaneous GMCSF or saline injections at the time of infarction. Molecular and haemodynamic assessments were performed at pre-determined time points following ligation. FINDINGS: SDF/GMCSF therapy upregulated EPC density as shown by flow cytometry (0.12±0.02% vs. 0.06±0.01% circulating lymphocytes, p=0.005), 48hours following infarction. A marked increase in perfusion was evident eight weeks after therapy, utilising confocal angiography (5.02±1.7×10(-2)μm(3)blood/μm(3)myocardial tissue vs. 2.03±0.710(-2)μm(3)blood/μm(3)myocardial tissue, p=0.00004). Planimetric analysis demonstrated preservation of wall thickness (0.98±0.09mm vs. 0.67±0.06mm, p=0.003) and ventricular diameter (7.81±0.99mm vs. 9.41±1.1mm, p=0.03). Improved haemodynamic function was evidenced by echocardiography and PV analysis (ejection fraction: 56.4±18.1% vs. 25.3±15.6%, p=0.001; pre-load adjusted maximal power: 6.6±2.6mW/μl(2) vs. 2.7±1.4mW/μl(2), p=0.01). CONCLUSION: Neovasculogenic therapy with GMCSF-mediated EPC upregulation and SDF-mediated EPC chemokinesis maybe an effective therapy for infarct modulation and preservation of myocardial function following acute myocardial infarction.
PURPOSE: Post-myocardial infarction heart failure is a major health concern with limited therapy. Molecular revascularisation utilising granulocyte-macrophage colony stimulating factor (GMCSF) mediated endothelial progenitor cell (EPC) upregulation and stromal cell derived factor-1α (SDF) mediated myocardial EPC chemokinesis, may prevent myocardial loss and adverse remodelling. Vasculogenesis, viability, and haemodynamic improvements following therapy were investigated. PROCEDURES: Lewis rats (n=91) underwent LAD ligation and received either intramyocardial SDF and subcutaneous GMCSF or saline injections at the time of infarction. Molecular and haemodynamic assessments were performed at pre-determined time points following ligation. FINDINGS: SDF/GMCSF therapy upregulated EPC density as shown by flow cytometry (0.12±0.02% vs. 0.06±0.01% circulating lymphocytes, p=0.005), 48hours following infarction. A marked increase in perfusion was evident eight weeks after therapy, utilising confocal angiography (5.02±1.7×10(-2)μm(3)blood/μm(3)myocardial tissue vs. 2.03±0.710(-2)μm(3)blood/μm(3)myocardial tissue, p=0.00004). Planimetric analysis demonstrated preservation of wall thickness (0.98±0.09mm vs. 0.67±0.06mm, p=0.003) and ventricular diameter (7.81±0.99mm vs. 9.41±1.1mm, p=0.03). Improved haemodynamic function was evidenced by echocardiography and PV analysis (ejection fraction: 56.4±18.1% vs. 25.3±15.6%, p=0.001; pre-load adjusted maximal power: 6.6±2.6mW/μl(2) vs. 2.7±1.4mW/μl(2), p=0.01). CONCLUSION: Neovasculogenic therapy with GMCSF-mediated EPC upregulation and SDF-mediated EPC chemokinesis maybe an effective therapy for infarct modulation and preservation of myocardial function following acute myocardial infarction.
Authors: Eiji Toyota; David C Warltier; Tommy Brock; Erik Ritman; Christopher Kolz; Peter O'Malley; Petra Rocic; Marta Focardi; William M Chilian Journal: Circulation Date: 2005-10-04 Impact factor: 29.690
Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Tiffany M Powell; Jonathan D Paul; Jonathan M Hill; Michael Thompson; Moshe Benjamin; Maria Rodrigo; J Philip McCoy; Elizabeth J Read; Hanh M Khuu; Susan F Leitman; Toren Finkel; Richard O Cannon Journal: Arterioscler Thromb Vasc Biol Date: 2004-11-29 Impact factor: 8.311
Authors: Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner Journal: Nat Med Date: 2004-07-04 Impact factor: 53.440
Authors: Ann C Gaffey; Minna H Chen; Chantel M Venkataraman; Alen Trubelja; Christopher B Rodell; Patrick V Dinh; George Hung; John W MacArthur; Renganaden V Soopan; Jason A Burdick; Pavan Atluri Journal: J Thorac Cardiovasc Surg Date: 2015-07-17 Impact factor: 5.209
Authors: William Hiesinger; Matthew J Brukman; Ryan C McCormick; J Raymond Fitzpatrick; John R Frederick; Elaine C Yang; Jeffrey R Muenzer; Nicole A Marotta; Mark F Berry; Pavan Atluri; Y Joseph Woo Journal: J Thorac Cardiovasc Surg Date: 2012-01-20 Impact factor: 5.209
Authors: William Hiesinger; Sergei A Vinogradov; Pavan Atluri; J Raymond Fitzpatrick; John R Frederick; Rebecca D Levit; Ryan C McCormick; Jeffrey R Muenzer; Elaine C Yang; Nicole A Marotta; John W MacArthur; David F Wilson; Y Joseph Woo Journal: J Appl Physiol (1985) Date: 2011-02-03
Authors: Pavan Atluri; Alen Trubelja; Alexander S Fairman; Philip Hsiao; John W MacArthur; Jeffrey E Cohen; Yasuhiro Shudo; John R Frederick; Y Joseph Woo Journal: Circulation Date: 2013-09-10 Impact factor: 29.690
Authors: Yasuhiro Shudo; Jeffrey E Cohen; John W Macarthur; Pavan Atluri; Philip F Hsiao; Elaine C Yang; Alexander S Fairman; Alen Trubelja; Jay Patel; Shigeru Miyagawa; Yoshiki Sawa; Y Joseph Woo Journal: Circulation Date: 2013-09-10 Impact factor: 29.690
Authors: John W MacArthur; Brendan P Purcell; Yasuhiro Shudo; Jeffrey E Cohen; Alex Fairman; Alen Trubelja; Jay Patel; Philip Hsiao; Elaine Yang; Kelsey Lloyd; William Hiesinger; Pavan Atluri; Jason A Burdick; Y Joseph Woo Journal: Circulation Date: 2013-09-10 Impact factor: 29.690